Why MacroGenics Stock Rocketed 70.5% Higher in February

FAN Editor

What happened

Shares of MacroGenics (NASDAQ: MGNX), a clinical-stage biotech focused on the cancer space, soared 70.5% last month, according to data from S&P Global Market Intelligence.

Continue Reading Below

For some context, the S&P 500 index returned 3.2% in February.

So what

We can attribute MacroGenics stock’s powerful performance last month to the company’s Feb. 6 announcement of positive results for its Phase 3 “Sophia” study of its HER2-positive breast cancer treatment drug candidate, margetuximab. Shares escalated following this announcement, closing the day with a 130% gain.

Patients treated with a combination of MacroGenics’ margetuximab and chemotherapy experienced a statistically significant 24% risk reduction in progression-free survival compared to those receiving Roche‘s Herceptin plus chemotherapy, according to the press release.

Last month’s big stock pop was no doubt particularly welcome among MacroGenics investors, given the stock’s poor performance over the last year and since its initial public offering in October 2013.

Now what

MacroGenics plans on filing for margetuximab’s approval with the U.S. Food and Drug Administration in the second half of this year. If approved, the drug should be a huge growth driver for many years, given that MacroGenics has a market cap of just $984 million and the market for drugs to treat HER2-positive breast cancer could be worth up to $10 billion annually by 2025, according to my colleague George Budwell, who quoted a report by GlobalData.

10 stocks we like better than MacroGenicsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and MacroGenics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 1, 2019

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Free America Network Articles

Leave a Reply

Next Post

Tokyo District Court says it has okayed Nissan ex-chairman Carlos Ghosn's release on 1 billion yen ($8.9 million) bail.

Quotes delayed at least 15 minutes. Real-time quotes provided by BATS BZX Real-Time Price. Market Data provided by Interactive Data (Terms & Conditions). Powered and Implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund and ETF data provided by […]